GlassScriptPhysician profile
Edmond Obeid
NPI 1508871070
$15,873.75
in general payments reported to CMS, 2019-2025
32 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,606 · 2020: $1,754 · 2021: $2,281 · 2022: $2,464 · 2023: $2,249 · 2024: $2,297 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,716 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,716.34 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,064.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,787.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,242.64 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,463.27 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,305.05 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $524.63 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $514.10 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $508.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $484.84 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $437.25 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $375.31 | 2022-2025 | |
| Abbott Laboratories | $367.98 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $346.84 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.85 | 2021-2023 | Xifaxan |
| Pfizer INC. | $177.70 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156.09 | 2024-2025 | |
| Glaxosmithkline, LLC. | $147.33 | 2019-2024 | Shingrix, Arexvy |
| Seqirus USA INC | $110.64 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Phathom Pharmaceuticals, INC. | $101.25 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $71.11 | 2022 | |
| Astellas Pharma US INC | $68.01 | 2025 | Veozah |
| Phadia US INC. | $62.31 | 2021-2023 | Immunocap |
| E.R. Squibb & Sons, L.L.C. | $52.75 | 2019-2020 | |
| Esperion Therapeutics, INC. | $51.54 | 2020 | |
| Madrigal Pharmaceuticals | $41.87 | 2025 | Rezdiffra |
| Mannkind Corporation | $35.25 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $23.72 | 2025 | Nuzyra |
| Galderma Laboratories, L.P. | $15.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2019 | |
| Medline Industries LP | $14.05 | 2022 | |
| Vistapharm, INC. | $13.38 | 2021 | |
| Philips North America LLC | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Obeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.